CN105477023A - Prescription for treating inflammatory bowel disease - Google Patents
Prescription for treating inflammatory bowel disease Download PDFInfo
- Publication number
- CN105477023A CN105477023A CN201510937002.8A CN201510937002A CN105477023A CN 105477023 A CN105477023 A CN 105477023A CN 201510937002 A CN201510937002 A CN 201510937002A CN 105477023 A CN105477023 A CN 105477023A
- Authority
- CN
- China
- Prior art keywords
- prescription
- intestinal tract
- intestinal
- inflammatory bowel
- layer barrier
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 208000022559 Inflammatory bowel disease Diseases 0.000 title abstract description 5
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims abstract description 10
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims abstract description 10
- 239000004473 Threonine Substances 0.000 claims abstract description 10
- 235000018417 cysteine Nutrition 0.000 claims abstract description 10
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims abstract description 10
- 241000222336 Ganoderma Species 0.000 claims description 11
- 230000002757 inflammatory effect Effects 0.000 claims description 10
- 230000000968 intestinal effect Effects 0.000 abstract description 24
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 23
- 239000000427 antigen Substances 0.000 abstract description 18
- 102000036639 antigens Human genes 0.000 abstract description 18
- 108091007433 antigens Proteins 0.000 abstract description 18
- 230000004888 barrier function Effects 0.000 abstract description 16
- 210000002175 goblet cell Anatomy 0.000 abstract description 13
- 210000001519 tissue Anatomy 0.000 abstract description 13
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract description 12
- 239000001301 oxygen Substances 0.000 abstract description 12
- 229910052760 oxygen Inorganic materials 0.000 abstract description 12
- 206010061218 Inflammation Diseases 0.000 abstract description 11
- 230000004054 inflammatory process Effects 0.000 abstract description 11
- 230000000694 effects Effects 0.000 abstract description 9
- 230000002159 abnormal effect Effects 0.000 abstract description 7
- 239000003814 drug Substances 0.000 abstract description 7
- 230000036770 blood supply Effects 0.000 abstract description 4
- 230000028993 immune response Effects 0.000 abstract description 4
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 abstract description 3
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 abstract description 3
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 abstract description 3
- 239000002994 raw material Substances 0.000 abstract description 3
- 240000008397 Ganoderma lucidum Species 0.000 abstract description 2
- 235000001637 Ganoderma lucidum Nutrition 0.000 abstract description 2
- 235000016709 nutrition Nutrition 0.000 abstract description 2
- 230000035764 nutrition Effects 0.000 abstract description 2
- 230000028327 secretion Effects 0.000 abstract description 2
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 230000003014 reinforcing effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 239000003795 chemical substances by application Substances 0.000 description 7
- 230000007812 deficiency Effects 0.000 description 6
- 230000003203 everyday effect Effects 0.000 description 6
- 230000001717 pathogenic effect Effects 0.000 description 6
- 102000001621 Mucoproteins Human genes 0.000 description 5
- 108010093825 Mucoproteins Proteins 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 210000000987 immune system Anatomy 0.000 description 5
- 244000005700 microbiome Species 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000000981 epithelium Anatomy 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 206010021143 Hypoxia Diseases 0.000 description 2
- 230000033289 adaptive immune response Effects 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000015788 innate immune response Effects 0.000 description 2
- 208000002551 irritable bowel syndrome Diseases 0.000 description 2
- 244000000010 microbial pathogen Species 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 102000007863 pattern recognition receptors Human genes 0.000 description 2
- 108010089193 pattern recognition receptors Proteins 0.000 description 2
- 101150063569 slgA gene Proteins 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010012742 Diarrhoea infectious Diseases 0.000 description 1
- 206010015084 Episcleritis Diseases 0.000 description 1
- 206010015226 Erythema nodosum Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 206010028034 Mouth ulceration Diseases 0.000 description 1
- 241000269799 Perca fluviatilis Species 0.000 description 1
- 241000269800 Percidae Species 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 206010039705 Scleritis Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000002052 anaphylactic effect Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 230000003870 intestinal permeability Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- -1 monoclonal antibody Substances 0.000 description 1
- 230000002969 morbid Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 208000009954 pyoderma gangrenosum Diseases 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/074—Ganoderma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Mycology (AREA)
- Zoology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention discloses a prescription for treating inflammatory bowel disease and belongs to the field of medicine. The prescription is based on the principle of reinforcing intestinal epithelial goblet cells, building a normal intestinal tract surface mucous layer barrier and stopping intestinal tract antigens from approaching, contacting, attaching and entering intestinal wall tissue to block abnormal immune response and occurrence of inflammation. The prescription has the advantages that ganoderma lucidum has the effect of enhancing blood supply and oxygen supply of a human body, and threonine, serine and cysteine are the key components of mucin; the prescription provides nutrition, oxygen and raw materials to the generation, renewal and repairing of the goblet cells and goblet cells' secretion of the mucin forming the intestinal tract surface mucous layer barrier; the prescription has evident effects of building the normal intestinal tract surface mucous layer barrier, stopping inflammation and repairing intestinal tract tissue and is good in curative effect on the inflammatory bowel disease.
Description
Technical field
The present invention relates to the Chinese crude drug for the treatment of inflammatory bowel and amino acid whose combination formula, belong to medicine field.
Background technology
Inflammatory bowel (inflammatoryboweldisease, IBD) is the disease that a kind of pathogenic factor and pathogenesis are not yet completely clear and definite.Because pathogenic factor and pathogenesis are illustrated not yet completely, old friends can not fundamentally stop or delay the progress of this disease course.
Medical Immunology is thought, immune system occurs abnormal to antigen recognition and tolerance, namely normally perches the improper identification of microorganism to intestinal and produces immunne response, cause this disease.Histology and Embryology is then thought, intestinal permeability is too high, causes a large amount of Intestinal Antigens to enter intestinal tissue, has caused the permanent responsing reaction of immune system and has caused this disease.
At present the treatment of inflammatory bowel is taken as the leading factor with Medical Immunology, primary treatment measure be intervene, Immunosuppression response and inflammation to the damage of intestinal, as used glucocorticoid, aminosalicyclic acid supplement, monoclonal antibody, immunosuppressant etc.Above-mentioned remedy measures effect is undesirable and side effect large, so, to the research of the inflammatory bowel cause of disease, find pathogenic factor, take corresponding remedy measures to be the instant task of medical circle.
Summary of the invention
The present invention is based on modern medicine, the basis probing into inflammatory bowel pathogenic factor proposes the remedy measures of oneself, namely intestinal tissue and epithelial goblet cell is reinforced, build normal intestinal tract surface slime layer barrier, stop Intestinal Antigens close, contact, adhere to and enter intestinal tissue, thus block the generation of abnormal immune response, stop the intestinal tissue of inflammation, repairing damage simultaneously.
If carrying out intervention to the immunne response occurred and inflammation is try to stop water from boiling by skimming it off and pouring it back, and prescription therapeutic measure so of the present invention is removing burning wood away under the boiler.
First the gut muco-membranous barrier of human body is intestinal tract surface slime layer barrier, and intestinal tract surface slime layer barrier is the first line of defence of gut muco-membranous barrier.What intestinal tract surface slime layer was secreted by gut epithelium goblet cell mucoproteinly forms.The function of normal intestinal tract surface slime layer be stop the microorganism in intestinal comprise pathogenic microorganism, normally perch microorganism close with food source property antigen, contact, adhere to and enter gut epithelium and intestinal walls, and " attempt " is passed through to microorganism particularly pathogenic microorganism performance adhesion and the effect of parcel of surperficial slime layer, avoid the generation of abnormal immune response and inflammation.
Intestinal slime layer barrier has certain fluctuation, causes a small amount of microbes antigen or food source property antigen to pass through intestinal tract surface slime layer, close, contact, adhere to and enter gut epithelium.These antigens passing through intestinal tract surface slime layer first identify by the pattern recognition receptors of inherent immunity system (PRRs) and cause innate immune response to remove antigen.
When innate immune response can not remove antigen, antigen can by antigen presenting cell (APC) as macrophage (Μ φ), dendritic cell (DC) etc. be absorbed, are offered and cause adaptive immune response.Adaptive immune response enters immune system in the Process of Antigen of intestinal tissue in removing can discharge a large amount of secretory immunoglobulin As (secretorylffA, slgA) to enteric cavity.Can be combined with antigen specifically after slgA releases people's enteric cavity, suppress or kill bacteria, neutralization virus, prevent antigen close, contact, adhere to and enter enteric epithelium, thus reach immunologic balance.
The imbalance of intestinal tract surface slime layer barrier cause Intestinal Antigens in a large number close, contact, adhere to and enter intestinal wall, immune system cannot remove antigen in time, thus immunologic balance is broken, exception throw immunne response and inflammation, damage intestinal tissue, this is the pathogenic factor of inflammatory bowel.
The reason of intestinal tract surface slime layer barrier imbalance may be the performance of goblet cell abnormal condition, comprises the defect of goblet cell, deficiency and renewal, dysfunction; Also may be that goblet cell secretes mucoprotein obstacle.The main cause that goblet cell abnormal condition and goblet cell secrete mucoprotein obstacle is that intestinal blood supply supplies hypoxgia or and has proteinacious malnutrition to cause intestinal cell metabolism substrate deficiency, synthesize mucoprotein insufficient raw material etc.
Content of the present invention is: the combination formula of Chinese crude drug Ganoderma and threonine, serine, cysteine.
Ganoderma has the effect strengthening blood of human body supply and oxygen supply.
The oxygen reserves of human body is relative to very pettiness nutrient deposit, and may cause damage because oxygen supply is not enough to human body when human body has excess oxygen consumption demand, old friend's body increases oxygen supply when morbid state particularly important.
Threonine, serine, cysteine are that goblet cell secretes mucoprotein primary raw material.
Apply formula of the present invention, intestinal tissue blood supply and oxygen supply can be strengthened, for the generation of goblet cell, reparation, renewal and normal work provide sufficient nutrition and oxygen, furnish ample material and oxygen for goblet cell secretion is mucoprotein, thus build normal intestinal tract surface slime layer barrier, stop Intestinal Antigens close, contact, adhere to and enter into intestinal tissue, stop the generation of abnormal immune response, and then reach the termination of inflammation and the reparation of intestinal tissue, the mechanism of action of Here it is prescription therapeutic inflammatory bowel of the present invention.
Pathologic data shows, Leukocyte Killing, degraded pathogen, antigen, fragment of tissue need to consume than the oxygen of many 2 ~ 20 times time normal, so the oxygen supply that inflammatory bowel patient strengthens inflammation part is extremely important to the efficiency of inflammation and the termination of inflammation.
Ganoderma of the present invention is the Ganoderma sporophore that the Pharmacopoeia of the People's Republic of China specifies, especially still do not discharge the ganoderma lucidum sporocarp of spore as well to be about to maturation, the consumption in detailed description of the invention measures with the sporophore of drying.
Formula of the present invention can be made into masticatory, containing agent and oral agents, with masticatory, best containing agent effect.
According to mucosal immune system (mucosalimmunesystem), the mucosa traversal system (mucosalmigrationsystem of Medical Immunology, MMS) and " immunity is patrolled and examined " theoretical, the imbalance of intestinal tract surface slime layer barrier can also cause the diseases such as such as periphery arthritis, erythema nodosum, Pyoderma gangrenosum, episcleritis, recurrent oral ulceration; The imbalance of intestinal tract surface slime layer barrier also may cause autoimmune disease, rheumatism and anaphylactic disease.The important research field that the relation of probing into intestinal tract surface slime layer barrier and disease will be 21 century preclinical medicine.Build normal intestinal tract surface slime layer barrier, the intestinal tissue of repairing damage is important content of the present invention, is the primary efficacy of formula of the present invention.
A large amount of facts have proved, applies prescription therapeutic irritable bowel syndrome of the present invention, infectious diarrhea, the long-term diarrhea of unknown cause, asthma, allergic rhinitis have reliable effect.
According to the theory of the combination of Chinese and Western medicine, the disease of human body comes from deficiency of vital energy blood deficiency mostly, and formula of the present invention can strengthen blood supply and the oxygen supply of human body integral, so have good therapeutical effect to the people of deficiency of vital energy blood deficiency.
Reinforce according to healthy and beautiful longevity and says, disease, the aging of human body are mostly relevant with body hypoxic-ischemic, solution body hypoxic-ischemic problem, and most of disease can prevention and therapy, and human longevity can significantly extend.
Detailed description of the invention
One, Ganoderma 0.5 gram, threonine 0.5 gram, serine 0.6 gram, cysteine 0.06 restraint are made masticatory, every day 2 to 4 times.
Two, Ganoderma 0.25 gram, threonine 0.25 gram, serine 0.3 gram, cysteine 0.03 restraint are made masticatory, every day 2 to 4 times.
Three, Ganoderma 0.5 gram, threonine 0.5 gram, serine 0.6 gram, cysteine 0.06 restraint are made containing agent, every day 2 to 4 times.
Four, Ganoderma 0.25 gram, threonine 0.25 gram, serine 0.3 gram, cysteine 0.03 restraint are made containing agent, every day 2 to 4 times.
Five, Ganoderma 5 grams, threonine 0.5 gram, serine 0.6 gram, cysteine 0.06 restraint are made oral agents, every day 2 to 4 times.
Six, Ganoderma 2.5 grams, threonine 0.25 gram, serine 0.3 gram, cysteine 0.03 restraint are made oral agents, every day 2 to 4 times.
Claims (1)
1. treat a prescription for inflammatory bowel, its prescription is characterized as: Ganoderma 5 ~ 50 parts, threonine 5 parts, serine 6 parts, cysteine 0.6 part.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510937002.8A CN105477023A (en) | 2015-12-16 | 2015-12-16 | Prescription for treating inflammatory bowel disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510937002.8A CN105477023A (en) | 2015-12-16 | 2015-12-16 | Prescription for treating inflammatory bowel disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105477023A true CN105477023A (en) | 2016-04-13 |
Family
ID=55664538
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510937002.8A Withdrawn CN105477023A (en) | 2015-12-16 | 2015-12-16 | Prescription for treating inflammatory bowel disease |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105477023A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20080011921A (en) * | 2006-08-01 | 2008-02-11 | 퓨리메드 주식회사 | Compositions for treating autoimmune disease containing extracts of salviae miltiorrhizae radix |
-
2015
- 2015-12-16 CN CN201510937002.8A patent/CN105477023A/en not_active Withdrawn
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20080011921A (en) * | 2006-08-01 | 2008-02-11 | 퓨리메드 주식회사 | Compositions for treating autoimmune disease containing extracts of salviae miltiorrhizae radix |
Non-Patent Citations (2)
| Title |
|---|
| ANNAÏG LAN ET AL: "Mucosal Healing in Inflammatory Bowel Diseases: Is There a Place for Nutritional Supplementation?", 《INFLAMM BOWEL DIS》 * |
| 何松庆: "咀嚼灵芝与肠道黏膜屏障--食物过敏、过敏性哮喘、口腔溃疡与炎症性肠病", 《医药卫生》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105362338A (en) | Composition for treating inflammatory bowel disease | |
| CN105412237A (en) | Composition for treating inflammatory bowel disease | |
| CN105412157A (en) | Composition for treating inflammatory bowel disease | |
| CN105343172A (en) | Prescription for treating inflammatory bowel disease | |
| CN105362306A (en) | Composition for treating inflammatory bowel disease | |
| CN105477023A (en) | Prescription for treating inflammatory bowel disease | |
| CN105412158A (en) | Composition for treating inflammatory bowel disease | |
| CN105434524A (en) | Composition for treating inflammatory bowel disease | |
| CN105362304A (en) | Composition for treating inflammatory bowel disease | |
| CN105456357A (en) | Formula for treating inflammatory bowel disease | |
| CN105412232A (en) | Composition for treating inflammatory bowel disease | |
| CN105456358A (en) | Formula for treating inflammatory bowel disease | |
| CN105412162A (en) | Combination formula for treating inflammatory bowel disease | |
| CN105412164A (en) | Composition for treating inflammatory bowel disease | |
| CN105412161A (en) | Combination formula for treating inflammatory bowel disease | |
| CN105343136A (en) | Prescription for treating inflammatory bowel disease | |
| CN105412229A (en) | Combination formula for treating inflammatory bowel disease | |
| CN105362303A (en) | Composition for treating inflammatory bowel disease | |
| CN105412241A (en) | Composition for treating inflammatory bowel disease | |
| CN105395606A (en) | Combined formula for treating inflammatory bowel disease | |
| CN105434523A (en) | Composition for treating inflammatory bowel disease | |
| CN105412230A (en) | Composition for treating inflammatory bowel disease | |
| CN105412231A (en) | Composition for treating inflammatory bowel disease | |
| CN105434526A (en) | Combination formula for treating inflammatory bowel disease | |
| CN105412163A (en) | Composition for treating inflammatory bowel disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20160413 |
|
| WW01 | Invention patent application withdrawn after publication |